Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux.
Cheng
Kit L
KL
Brody
Judith
J
Warshall
Craig E
CE
Sloand
Elaine M
EM
Allen
Steven L
SL
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D000077425:Fondaparinux; D006457:Hemoglobinuria, Paroxysmal / Q000139:chemically induced* / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy*; D019338:Polypharmacy; D011134:Polysaccharides / Q000008:administration & dosage*; D012008:Recurrence; D013927:Thrombosis / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000925:Anticoagulants; D007166:Immunosuppressive Agents; D011134:Polysaccharides; D000074323:Alemtuzumab; C481642:eculizumab; D000077425:Fondaparinux